Loading...
Header Logo
Keywords
Last Name
Institution

JEFFREY SCOTT WEFEL

TitleAssociate Professor
InstitutionMD Anderson
DepartmentNeuro-Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Wefel JS. Opportunities to enhance our management, outcomes, and interventions for patients with CNS malignancy. Neurooncol Pract. 2019 Jul; 6(4):247-248. PMID: 31386055.
      View in: PubMed
    2. Noll KR, Bradshaw ME, Parsons MW, Dawson EL, Rexer J, Wefel JS. Monitoring of Neurocognitive Function in the Care of Patients with Brain Tumors. Curr Treat Options Neurol. 2019 Jun 28; 21(7):33. PMID: 31250277.
      View in: PubMed
    3. van Lonkhuizen PJC, Klaver KM, Wefel JS, Sitskoorn MM, Schagen SB, Gehring K. Interventions for cognitive problems in adults with brain cancer: A narrative review. Eur J Cancer Care (Engl). 2019 May; 28(3):e13088. PMID: 31090162.
      View in: PubMed
    4. Noll KR, Sullaway CM, Wefel JS. Depressive symptoms and executive function in relation to survival in patients with glioblastoma. J Neurooncol. 2019 Mar; 142(1):183-191. PMID: 30680509.
      View in: PubMed
    5. Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ, Movsas B. Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. Neurosurgery. 2019 01 01; 84(1):66-76. PMID: 29618054.
      View in: PubMed
    6. Laack NN, Pugh SL, Brown PD, Fox S, Wefel JS, Meyers C, Choucair A, Khuntia D, Suh JH, Roberge D, Wendland MM, Bruner D. The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. Neurooncol Pract. 2019 Jul; 6(4):274-282. PMID: 31386073.
      View in: PubMed
    7. Harrison RA, Kesler SR, Johnson JM, Penas-Prado M, Sullaway CM, Wefel JS. Neurocognitive dysfunction in adult cerebellar medulloblastoma. Psychooncology. 2019 01; 28(1):131-138. PMID: 30315720.
      View in: PubMed
    8. Wefel JS. Food for thought: patient outcomes, diagnostic challenges, and therapeutic possibilities. Neurooncol Pract. 2018 Nov; 5(4):203. PMID: 31385963.
      View in: PubMed
    9. Harrison RA, Wefel JS. Neurocognitive Function in Adult Cancer Patients. Neurol Clin. 2018 08; 36(3):653-674. PMID: 30072075.
      View in: PubMed
    10. Hardy SJ, Krull KR, Wefel JS, Janelsins M. Cognitive Changes in Cancer Survivors. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:795-806. PMID: 30231372.
      View in: PubMed
    11. Noll KR, Bradshaw ME, Rexer J, Wefel JS. Neuropsychological Practice in the Oncology Setting. Arch Clin Neuropsychol. 2018 May 01; 33(3):344-353. PMID: 29718081.
      View in: PubMed
    12. Wefel JS. Patient-centered care in neuro-oncology. Neurooncol Pract. 2018 Mar; 5(1):1. PMID: 31385979.
      View in: PubMed
    13. Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffietti R, van den Bent MJ, Wefel JS, Wen PY. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018 01; 19(1):e20-e32. PMID: 29304358.
      View in: PubMed
    14. Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018 01; 19(1):e33-e42. PMID: 29304360.
      View in: PubMed
    15. Wefel JS, Parsons MW, Gondi V, Brown PD. Neurocognitive aspects of brain metastasis. Handb Clin Neurol. 2018; 149:155-165. PMID: 29307352.
      View in: PubMed
    16. Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V. Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? J Clin Oncol. 2018 02 10; 36(5):483-491. PMID: 29272161.
      View in: PubMed
    17. Wefel JS. Choosing clinical trial endpoints, aggregating data, and making clinical decisions. Neurooncol Pract. 2017 Dec; 4(4):199-200. PMID: 31385989.
      View in: PubMed
    18. Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS. Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Mol Cell Neurosci. 2018 01; 86:65-71. PMID: 29180229.
      View in: PubMed
    19. Noll KR, Bradshaw ME, Weinberg JS, Wefel JS. Neurocognitive functioning is associated with functional independence in newly diagnosed patients with temporal lobe glioma. Neurooncol Pract. 2018 Aug; 5(3):184-193. PMID: 30094046.
      View in: PubMed
    20. Schagen SB, Wefel JS. Post-traumatic Stress as the Primary Cause for Cognitive Decline-Not the Whole Story, and Perhaps No Story at All. J Natl Cancer Inst. 2017 10 01; 109(10). PMID: 28521366.
      View in: PubMed
    21. Salek KE, Hassan IS, Kotrotsou A, Abrol S, Faro SH, Mohamed FB, Zinn PO, Wei W, Li N, Kumar AJ, Weinberg JS, Wefel JS, Kesler SR, Liu HA, Hou P, Stafford RJ, Prabhu S, Sawaya R, Colen RR. Silent Sentence Completion Shows Superiority Localizing Wernicke's Area and Activation Patterns of Distinct Language Paradigms Correlate with Genomics: Prospective Study. Sci Rep. 2017 09 21; 7(1):12054. PMID: 28935966.
      View in: PubMed
    22. Armstrong TS, Vera E, Zhou R, Acquaye AA, Sullaway CM, Berger AM, Breton G, Mahajan A, Wefel JS, Gilbert MR, Bondy M, Scheurer ME. Association of genetic variants with fatigue in patients with malignant glioma. Neurooncol Pract. 2018 May; 5(2):122-128. PMID: 31386001.
      View in: PubMed
    23. Hansen CC, Smith JB, Mohamed ASR, Mulcahy CF, Wefel JS, Hutcheson KA, Chrane K, Phan J, Frank SJ, Garden AS, Smith BD, Eichelberger H, Anderson C, McCoy C, Horiates M, Patrick C, Floris S, French C, Beadle BM, Morrison WH, Su SY, Lewis CM, Kupferman ME, Johnson JM, Skinner HD, Lai SY, Hanna EY, Rosenthal DI, Fuller CD, Gunn GB. Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. Head Neck. 2017 10; 39(10):2048-2056. PMID: 28763137.
      View in: PubMed
    24. Wefel JS, Noll KR, Rao G, Cahill DP. Reply to Freyschlag et al. Neuro Oncol. 2017 04 01; 19(4):598-599. PMID: 28339696.
      View in: PubMed
    25. Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 03; 132(1):181-188. PMID: 28116649.
      View in: PubMed
    26. Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS. TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging (Albany NY). 2016 12 16; 8(12):3507-3519. PMID: 27992857.
      View in: PubMed
    27. Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. J Neurooncol. 2017 02; 131(3):565-574. PMID: 27848136.
      View in: PubMed
    28. Wefel JS. Neuro-Oncology Practice: Learning from our past to guide our future. Neurooncol Pract. 2016 Dec; 3(4):209-210. PMID: 31386053.
      View in: PubMed
    29. Wefel JS, Noll KR, Rao G, Cahill DP. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol. 2016 12; 18(12):1656-1663. PMID: 27576872.
      View in: PubMed
    30. Manchon JF, Dabaghian Y, Uzor NE, Kesler SR, Wefel JS, Tsvetkov AS. Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons. Sci Rep. 2016 05 11; 6:25705. PMID: 27168474.
      View in: PubMed
    31. Day J, Yust-Katz S, Cachia D, Wefel J, Katz LH, Tremont I, Bulbeck H, Armstrong T, Rooney AG. Interventions for the management of fatigue in adults with a primary brain tumour. Cochrane Database Syst Rev. 2016 Apr 13; 4:CD011376. PMID: 27074263.
      View in: PubMed
    32. Noll KR, Ziu M, Weinberg JS, Wefel JS. Neurocognitive functioning in patients with glioma of the left and right temporal lobes. J Neurooncol. 2016 06; 128(2):323-31. PMID: 27022915.
      View in: PubMed
    33. Wefel JS, Noll KR, Scheurer ME. Neurocognitive functioning and genetic variation in patients with primary brain tumours. Lancet Oncol. 2016 Mar; 17(3):e97-e108. PMID: 26972863.
      View in: PubMed
    34. Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro Oncol. 2016 Mar; 18 Suppl 2:ii13-ii20. PMID: 26989128.
      View in: PubMed
    35. Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52. PMID: 26834058.
      View in: PubMed
    36. Noll KR, Bradshaw ME, Weinberg JS, Wefel JS. Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma. Psychooncology. 2017 05; 26(5):617-624. PMID: 26677053.
      View in: PubMed
    37. Wefel JS. Cancer neurology, neuro-oncology, and clinical decision making. Neurooncol Pract. 2015 Dec; 2(4):159-160. PMID: 31386062.
      View in: PubMed
    38. Noll KR, Weinberg JS, Ziu M, Wefel JS. Verbal Learning Processes in Patients with Glioma of the Left and Right Temporal Lobes. Arch Clin Neuropsychol. 2016 Feb; 31(1):37-46. PMID: 26537777.
      View in: PubMed
    39. Noll KR, Weinberg JS, Ziu M, Benveniste RJ, Suki D, Wefel JS. Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma. Neurosurgery. 2015 Nov; 77(5):777-85. PMID: 26317672.
      View in: PubMed
    40. Noll KR, Wefel JS. Response to "From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function". Neuro Oncol. 2015 Oct; 17(10):1421-2. PMID: 26395063.
      View in: PubMed
    41. Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancré V, Lange M, Castel H. Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. J Pain Symptom Manage. 2015 Dec; 50(6):830-41. PMID: 26344551.
      View in: PubMed
    42. Liu Y, Zhou R, Sulman EP, Scheurer ME, Boehling N, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Conrad CA, Gilbert MR, Armstrong TS, Bondy ML, Wefel JS. Genetic Modulation of Neurocognitive Function in Glioma Patients. Clin Cancer Res. 2015 Jul 15; 21(14):3340-6. PMID: 25904748.
      View in: PubMed
    43. Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015 Mar; 65(2):123-38. PMID: 25483452.
      View in: PubMed
    44. Wefel JS. Neuro-Oncology Practice: Time Flies When You Are Having Fun! Neurooncol Pract. 2014 Dec; 1(4):143-144. PMID: 26034625.
      View in: PubMed
    45. Noll KR, Sullaway C, Ziu M, Weinberg JS, Wefel JS. Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. Neuro Oncol. 2015 Apr; 17(4):580-7. PMID: 25227126.
      View in: PubMed
    46. Schagen SB, Klein M, Reijneveld JC, Brain E, Deprez S, Joly F, Scherwath A, Schrauwen W, Wefel JS. Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions. EJC Suppl. 2014 Jun; 12(1):29-40. PMID: 26217164.
      View in: PubMed
    47. Gilbert MR, Dignam J, Pugh S, Armstrong TS, Wefel JS, Aldape K, Stupp R, Hegi M, Won M, Curran WJ, Mehta MP. Reply to M.C. Chamberlain. J Clin Oncol. 2014 May 20; 32(15):1634-5. PMID: 24752060.
      View in: PubMed
    48. Wefel JS, Kornet RL, Schagen SB. Systemically treated breast cancer patients and controls: an evaluation of the presence of noncredible performance. J Int Neuropsychol Soc. 2014 Apr; 20(4):357-69. PMID: 24607070.
      View in: PubMed
    49. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20; 370(8):699-708. PMID: 24552317.
      View in: PubMed
    50. Wefel JS, Vidrine DJ, Marani SK, Swartz RJ, Veramonti TL, Meyers CA, Hoekstra HJ, Hoekstra-Weebers JE, Gritz ER. A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology. 2014 Jun; 23(6):626-33. PMID: 24339329.
      View in: PubMed
    51. Kesler SR, Watson C, Koovakkattu D, Lee C, O'Hara R, Mahaffey ML, Wefel JS. Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav. 2013 Dec; 7(4):501-10. PMID: 23536015.
      View in: PubMed
    52. Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013 Nov 10; 31(32):4076-84. PMID: 24101048.
      View in: PubMed
    53. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ, Mehta MP. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013 Nov 10; 31(32):4085-91. PMID: 24101040.
      View in: PubMed
    54. Jones D, Vichaya EG, Wang XS, Sailors MH, Cleeland CS, Wefel JS. Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer. 2013 Dec 01; 119(23):4188-95. PMID: 24105672.
      View in: PubMed
    55. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e396-406. PMID: 23993384.
      View in: PubMed
    56. Schagen SB, Wefel JS. Chemotherapy-related changes in cognitive functioning. EJC Suppl. 2013 Sep; 11(2):225-32. PMID: 26217131.
      View in: PubMed
    57. Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e407-16. PMID: 23993385.
      View in: PubMed
    58. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013 Oct; 15(10):1429-37. PMID: 23956241.
      View in: PubMed
    59. Welsh JW, McGovern SL, Wefel JS, Komaki R, Brown PD, Soh HE. Reply to v.R. Bhatt et Al and m.C. Chamberlain. J Clin Oncol. 2013 Sep 01; 31(25):3165-6. PMID: 23943829.
      View in: PubMed
    60. Kesler SR, Wefel JS, Hosseini SM, Cheung M, Watson CL, Hoeft F. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc Natl Acad Sci U S A. 2013 Jul 09; 110(28):11600-5. PMID: 23798392.
      View in: PubMed
    61. Johnson DR, Wefel JS. Relationship between cognitive function and prognosis in glioblastoma. CNS Oncol. 2013 Mar; 2(2):195-201. PMID: 25057978.
      View in: PubMed
    62. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013 Mar 01; 31(7):895-902. PMID: 23341526.
      View in: PubMed
    63. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012 Jun; 12(3):267-75. PMID: 22453825.
      View in: PubMed
    64. Johnson DR, Sawyer AM, Meyers CA, O'Neill BP, Wefel JS. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol. 2012 Jun; 14(6):808-16. PMID: 22508762.
      View in: PubMed
    65. Armstrong TS, Wefel JS, Gning I, Acquaye A, Vera-Bolanos E, Gilbert MR, Cleeland CS, Mendoza T. Congruence of primary brain tumor patient and caregiver symptom report. Cancer. 2012 Oct 15; 118(20):5026-37. PMID: 22415423.
      View in: PubMed
    66. Schapiro R, Ferson D, Prabhu SS, Tummula S, Wefel J, Rao G. A technique for mapping cortical areas associated with speech arrest. Stereotact Funct Neurosurg. 2012; 90(2):118-23. PMID: 22398728.
      View in: PubMed
    67. Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, Wefel JS. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol. 2012 Mar; 107(1):165-74. PMID: 21964738.
      View in: PubMed
    68. Wu AS, Witgert ME, Lang FF, Xiao L, Bekele BN, Meyers CA, Ferson D, Wefel JS. Neurocognitive function before and after surgery for insular gliomas. J Neurosurg. 2011 Dec; 115(6):1115-25. PMID: 21905800.
      View in: PubMed
    69. Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jun; 13(6):660-8. PMID: 21558074.
      View in: PubMed
    70. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 Jun; 12(6):583-93. PMID: 21474379.
      View in: PubMed
    71. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1487-95. PMID: 20399573.
      View in: PubMed
    72. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011 Jul; 12(7):703-8. PMID: 21354373.
      View in: PubMed
    73. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61. PMID: 21310734.
      View in: PubMed
    74. Wefel JS, Vidrine DJ, Veramonti TL, Meyers CA, Marani SK, Hoekstra HJ, Hoekstra-Weebers JE, Shahani L, Gritz ER. Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer. 2011 Jan 01; 117(1):190-6. PMID: 20737560.
      View in: PubMed
    75. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010 Jul 15; 116(14):3348-56. PMID: 20564075.
      View in: PubMed
    76. Perrier ND, Balachandran D, Wefel JS, Jimenez C, Busaidy N, Morris GS, Dong W, Jackson E, Weaver S, Gantela S, Evans DB, Grubbs EG, Lee JE. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism. Surgery. 2009 Dec; 146(6):1116-22. PMID: 19879613.
      View in: PubMed
    77. Benge JF, Perrier ND, Massman PJ, Meyers CA, Kayl AE, Wefel JS. Cognitive and affective sequelae of primary hyperparathyroidism and early response to parathyroidectomy. J Int Neuropsychol Soc. 2009 Nov; 15(6):1002-11. PMID: 19807940.
      View in: PubMed
    78. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009 Nov; 10(11):1037-44. PMID: 19801201.
      View in: PubMed
    79. Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA. Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol. 2009 Nov; 24(7):689-98. PMID: 19767298.
      View in: PubMed
    80. Wefel JS. NovaMin: likely clinical success. Adv Dent Res. 2009; 21(1):40-3. PMID: 19717409.
      View in: PubMed
    81. Pitts NB, Wefel JS. Remineralization/desensitization: what is known? What is the future? Adv Dent Res. 2009; 21(1):83-6. PMID: 19717415.
      View in: PubMed
    82. Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist. 2008 Dec; 13(12):1285-95. PMID: 19019972.
      View in: PubMed
    83. Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev. 2008 Jun; 18(2):121-31. PMID: 18415683.
      View in: PubMed
    84. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008 Apr; 10(2):208-15. PMID: 18316473.
      View in: PubMed
    85. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008 Apr; 19(4):623-9. PMID: 17974553.
      View in: PubMed
    86. Mittendorf EA, Wefel JS, Meyers CA, Doherty D, Shapiro SE, Lee JE, Evans DB, Perrier ND. Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocr Pract. 2007 Jul-Aug; 13(4):338-44. PMID: 17669708.
      View in: PubMed
    87. Chang EL, Wefel JS, Maor MH, Hassenbusch SJ, Mahajan A, Lang FF, Woo SY, Mathews LA, Allen PK, Shiu AS, Meyers CA. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery. 2007 Feb; 60(2):277-83; discussion 283-4. PMID: 17290178.
      View in: PubMed
    88. Kayl AE, Wefel JS, Meyers CA. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther. 2006 Jul-Aug; 13(4):362-9. PMID: 16858172.
      View in: PubMed
    89. Heflin LH, Meyerowitz BE, Hall P, Lichtenstein P, Johansson B, Pedersen NL, Gatz M. Re: Cancer as a risk factor for dementia: a house built on shifting sand. J Natl Cancer Inst. 2005 Oct 19; 97(20):1550-1; author reply 1551-2. PMID: 16234571.
      View in: PubMed
    90. Wefel JS, Meyers CA. Cancer as a risk factor for dementia: a house built on shifting sand. J Natl Cancer Inst. 2005 Jun 01; 97(11):788-9. PMID: 15928294.
      View in: PubMed
    91. Maruff P, Falleti MG, Collie A. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Results of a prospective, randomized, longitudinal trial. Cancer. 2004 Nov 01; 101(9):2143-4; author reply 2144-5. PMID: 15382092.
      View in: PubMed
    92. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer. 2004 Aug 01; 101(3):466-75. PMID: 15274059.
      View in: PubMed
    93. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004 Jun 01; 100(11):2292-9. PMID: 15160331.
      View in: PubMed
    94. Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer. 2004 May 04; 90(9):1691-6. PMID: 15150608.
      View in: PubMed
    95. Atchison TB, Sander AM, Struchen MA, High WM, Roebuck TM, Contant CF, Wefel JS, Novack TA, Sherer M. Relationship between neuropsychological test performance and productivity at 1-year following traumatic brain injury. Clin Neuropsychol. 2004 May; 18(2):249-65. PMID: 15587672.
      View in: PubMed
    96. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003 Oct 01; 21(19):3557-8. PMID: 12913103.
      View in: PubMed
    97. AL-Helal AS, Armstrong SR, Xie XJ, Wefel JS. Effect of smear layer on root demineralization adjacent to resin-modified glass ionomer. J Dent Res. 2003 Feb; 82(2):146-50. PMID: 12562890.
      View in: PubMed
    98. Wefel JS, Stanford CM, Ament DK, Hogan MM, Harless JD, Pfarrer AM, Ramsey LL, Leusch MS, Biesbrock AR. In situ evaluation of sodium hexametaphosphate-containing dentifrices. Caries Res. 2002 Mar-Apr; 36(2):122-8. PMID: 12037369.
      View in: PubMed
    99. Levy SM, Warren JJ, Davis CS, Kirchner HL, Kanellis MJ, Wefel JS. Patterns of fluoride intake from birth to 36 months. J Public Health Dent. 2001; 61(2):70-7. PMID: 11474917.
      View in: PubMed
    100. Jensen ME, Donly K, Wefel JS. Assessment of the effect of selected snack foods on the remineralization/demineralization of enamel and dentin. J Contemp Dent Pract. 2000 Aug 15; 1(3):1-17. PMID: 12167879.
      View in: PubMed
    101. Heilman JR, Kiritsy MC, Levy SM, Wefel JS. Assessing fluoride levels of carbonated soft drinks. J Am Dent Assoc. 1999 Nov; 130(11):1593-9. PMID: 10573939.
      View in: PubMed
    102. Wefel JS, Hoyt BD, Massma PJ. Neuropsychological functioning in depressed versus nondepressed participants with Alzheimer's disease. Clin Neuropsychol. 1999 Aug; 13(3):249-57. PMID: 10726596.
      View in: PubMed
    103. Donly KJ, Segura A, Wefel JS, Hogan MM. Evaluating the effects of fluoride-releasing dental materials on adjacent interproximal caries. J Am Dent Assoc. 1999 Jun; 130(6):817-25. PMID: 10377639.
      View in: PubMed
    104. Hsu CY, Donly KJ, Drake DR, Wefel JS. Effects of aged fluoride-containing restorative materials on recurrent root caries. J Dent Res. 1998 Feb; 77(2):418-25. PMID: 9465175.
      View in: PubMed
    105. Ettinger RL, Olson RJ, Wefel JS, Asmussen C. In vitro evaluation of topical fluorides for overdenture abutments. J Prosthet Dent. 1997 Sep; 78(3):309-14. PMID: 9297649.
      View in: PubMed
    106. Suhr J, Tranel D, Wefel J, Barrash J. Memory performance after head injury: contributions of malingering, litigation status, psychological factors, and medication use. J Clin Exp Neuropsychol. 1997 Aug; 19(4):500-14. PMID: 9342686.
      View in: PubMed
    107. Heilman JR, Kiritsy MC, Levy SM, Wefel JS. Fluoride concentrations of infant foods. J Am Dent Assoc. 1997 Jul; 128(7):857-63. PMID: 9231600.
      View in: PubMed
    108. Segura A, Donly KJ, Wefel JS. The effects of microabrasion on demineralization inhibition of enamel surfaces. Quintessence Int. 1997 Jul; 28(7):463-6. PMID: 9477896.
      View in: PubMed
    109. Marinelli CB, Donly KJ, Wefel JS, Jakobsen JR, Denehy GE. An in vitro comparison of three fluoride regimens on enamel remineralization. Caries Res. 1997; 31(6):418-22. PMID: 9353580.
      View in: PubMed
    110. Heilman JR, Jordan TH, Warwick R, Wefel JS. Remineralization of root surfaces demineralized in solutions of differing fluoride levels. Caries Res. 1997; 31(6):423-8. PMID: 9353581.
      View in: PubMed
    111. ten Cate JM, Dundon KA, Vernon PG, Damato FA, Huntington E, Exterkate RA, Wefel JS, Jordan T, Stephen KW, Roberts AJ. Preparation and measurement of artificial enamel lesions, a four-laboratory ring test. Caries Res. 1996; 30(6):400-7. PMID: 8946105.
      View in: PubMed
    112. Wefel JS. Working Group Report 2: In situ caries models, saliva, microbiology, and statistical considerations. Adv Dent Res. 1995 Nov; 9(3):335-7. PMID: 8615953.
      View in: PubMed
    113. Wefel JS, Jensen ME, Triolo PT, Faller RV, Hogan MM, Bowman WD. De/remineralization from sodium fluoride dentifrices. Am J Dent. 1995 Aug; 8(4):217-20. PMID: 7576392.
      View in: PubMed
    114. Wefel JS, Heilman JR, Jordan TH. Comparisons of in vitro root caries models. Caries Res. 1995; 29(3):204-9. PMID: 7621496.
      View in: PubMed
    115. Drake DR, Wefel JS, Dunkerson D, Hogle K. The antimicrobial activity of Prevention mouthrinse. Am J Dent. 1993 Oct; 6(5):239-42. PMID: 7880467.
      View in: PubMed
    116. Triolo PT, Wefel JS, Jensen ME. Fluoride-releasing core build-up materials and artificial caries. Am J Dent. 1991 Oct; 4(5):207-10. PMID: 1810328.
      View in: PubMed
    117. Sheth JJ, Jesen ME, Wefel JS, Levy SM. Restoration of root caries with dentinal bonding agent and microfilled composite resin: 1-year clinical evaluation. Gerodontics. 1988 Apr; 4(2):71-7. PMID: 3061862.
      View in: PubMed
    118. Wefel JS, Harless JD. The use of saturated DCPD in remineralization of artificial caries lesions in vitro. J Dent Res. 1987 Nov; 66(11):1640-3. PMID: 10872398.
      View in: PubMed
    119. Neurocognitive effects.
    120. Cognitive complaints after breast cancer treatments. Breast Diseases. 25:92-93.
    121. Whole-brain irradiation for patients with brain metastases. The Lancet Oncology. 11:223.
    122. Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma. Psycho-Oncology.
    123. Chemotherapy-related changes in cognitive functioning. European Journal of Cancer, Supplement. 11:225-232.
    124. Monitoring and optimising cognitive function in cancer patients. European Journal of Cancer, Supplement. 12:29-40.
    125. Verbal Learning Processes in Patients with Glioma of the Left and Right Temporal Lobes. Archives of Clinical Neuropsychology. 31:37-46.
    126. Catechol-o-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Breast Diseases. 22:411-412.
    127. Impact of Cancer and Its Treatments on Cognitive Function. Journal of Pain and Symptom Management. 50:830-841.
    128. Neurocognitive functioning in patients with glioma of the left and right temporal lobes. Journal of Neuro-Oncology. 1-9.
    129. Erratum. International Journal of Radiation Oncology Biology Physics. 84.
    130. Neuropsychological assessment of adults with cancer. 44-55.
    131. Reply to acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 117:1103.
    132. Cognitive dysfunction related to chemotherapy and biological response modifiers. 97-114.
    133. Clinical outcome assessment in malignant glioma trials. Neuro-Oncology. 18:ii13-ii20.
    134. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. Journal of Neuro-Oncology. 1-10.
    135. Neurocognitive changes associated with surgical resection of left and right temporal lobe glioma. Neurosurgery. 77:777-785.
    136. A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine. 370:699-708.
    137. Erratum. Current Neurology and Neuroscience Reports. 12:340.
    138. Genetic modulation of neurocognitive function in glioma patients. Clinical Cancer Research. 21:3340-3346.
    139. Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons. Scientific Reports. 6.
    140. Neurocognitive testing in clinical trials. 320-328.
    WEFEL's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description